Online inquiry

IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ4628MR)

This product GTTS-WQ4628MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & 5-Methoxy-UTP. It ecodes the monoclonal antibody that targets LAG3 gene. The antibody can be applied in Non-Hodgkin's lymphoma (NHL) research.
Specifications
Product type mRNA
Modified bases 5-Methoxy-UTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_002286.6
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 3902
UniProt ID P18627
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-LAG3, BMS-986016(Cap 1, 5-Methoxy-UTP, 120 nt-poly(A)) (GTTS-WQ4628MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6709MR IVTScrip™ mRNA-Anti-EGFR, DS 1024(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA DS 1024
GTTS-WQ7831MR IVTScrip™ mRNA-Anti-GLP1R, GSK 716155(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA GSK 716155
GTTS-WQ15028MR IVTScrip™ mRNA-Anti-CSF1R, SNDX-6352(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA SNDX-6352
GTTS-WQ11181MR IVTScrip™ mRNA-Anti-TNFRSF4, MEDI0562(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA MEDI0562
GTTS-WQ6017MR IVTScrip™ mRNA-Anti-IL12B, CNTO 1275(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CNTO 1275
GTTS-WQ11891MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ10287MR IVTScrip™ mRNA-Anti-PCSK9, LGT209(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA LGT209
GTTS-WQ729MR IVTScrip™ mRNA-Anti-TNFSF13B, A-623(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA A-623
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW